NDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 2006
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
TRAVATAN Z (travoprost) by Novartis is acid, a prostaglandin analog is a selective fp prostanoid receptor agonist, which is believed to reduce iop by increasing uveoscleral outflow. Approved for ocular hypertension, open-angle glaucoma, glaucoma. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVATAN Z is a prostaglandin analog ophthalmic solution containing travoprost, approved by the FDA in September 2006. It is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. The drug works as a selective FP prostanoid receptor agonist that increases uveoscleral outflow to lower IOP. It represents a first-line topical therapy in the glaucoma treatment landscape and is manufactured by Novartis.
$0.0BPart D
3.4 years to LOEMechanism of Action
acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Pharmacologic Class:
Prostaglandin Analog
Indications (3)
Worked on TRAVATAN Z at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.